Close this search box.

Global Medtech CRO, NAMSA, announces strategic outsourcing partnership with Terumo Aortic

TOLEDO, OHIO and SUNRISE, FLORIDA – BUSINESSWIRE — JUNE 21, 2023 — NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and Terumo Aortic, a developer of aorta-focused medical devices, announced that they have entered into a strategic outsourcing partnership to assist with the acceleration and commercialization of Terumo Aortic’s innovative […]

Terumo Aortic announces launch of the global Thoraflex Hybrid extend study

Terumo Aortic today announced the launch of the company’s global Post-Approval Study (PAS) known as EXTEND for Thoraflex Hybrid, the only Frozen Elephant Trunk (FET) device approved by the US Food and Drug Administration (FDA) for the treatment of patients with complex aortic arch disease. This study is a prospective, multi-center, non-randomized, single arm, all-comers, […]

Terumo Aortic announces FDA approval of dissection and transection indication expansion for the Relay®Pro Stent-Graft system in the United States

Relay®Pro delivers uncompromised clinical performance in the lowest commercially available profile and is indicated for all pathologies of the descending thoracic artery; aneurysm, penetrating atherosclerotic ulcers, transection and dissection. Relay®Pro offers unparalleled accuracy, proven efficacy and durability as well as the widest range of sizes, tapering and configurations on the market, designed to expand the […]

Atrium Opening Signals Ambition

The opening ceremony, performed by CEO Erik Pomp and Brian Coll, the longest serving member of the Terumo Aortic family with over 37 years’ service, marks a major milestone in our investment project which will see over £50 million spent to expand and develop the manufacturing site. Erik Pomp, CEO of Terumo Aortic, commented: “We […]

Terumo Aortic announces enrolment of patients in an all-comers TREO AAA study

The TREO Abdominal Stent-Graft System is approved by the US Food and Drug Administration (FDA) to treat patients with abdominal aortic aneurysms. This is a prospective, multi-center, non-randomised, single-arm, post-market study; the purpose is to evaluate the real world, long-term performance of the device as a treatment for patients with infrarenal abdominal aortic aneurysms or […]

Terumo Aortic announces US FDA approval for Thoraflex Hybrid

Thoraflex Hybrid is the first of its kind device used in Frozen Elephant Trunk (FET) repair in the United States and was granted Breakthrough Device Designation by the FDA in 2020. Thoraflex Hybrid is a single use medical device combining a Gelweave polyester graft with a Nitinol self-expanding stent graft and is indicated for the […]

Terumo Aortic announces US FDA breakthrough device designation for RelayBranch

The RelayBranch Thoracic Stent-Graft System is implanted in patients with thoracic aortic arch pathologies requiring treatment that includes coverage of the innominate and left common carotid arteries. The purpose of the FDA’s Breakthrough Device Designation program is to fast-track the regulatory review process for certain medical technologies and device-led combination products that satisfy certain criteria; […]

Latest news

Subscribe for Email Updates

Your subscription could not be saved. Please try again.
Please check your email to confirm your subscription.

Subscribe to our regular email news to keep you updated on the latest information and events from Terumo Aortic.

We use Brevo as our marketing platform. By clicking below to submit this form, you acknowledge that the information you provided will be transferred to Brevo for processing in accordance with their terms of use